Achillion Pharmaceuticals News
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsYahoo 03/07 16:03 ET
NEW HAVEN, Conn. -- Achillion Pharmaceuticals, Inc. today reported financial results for the three and twelve months ended December 31, 2013.
It's a mistake to buy these shares before any real announcement about when the new hepatitis-C drugs will come to market.
The No. 1 stock on this list has more than half its float short.
Achillion Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 10% on the day.
NEW HAVEN, Conn. -- Achillion Pharmaceuticals, Inc. announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor ...
6:30 am Achillion Pharma reports HCV pipeline progress and outlines 2014 HCV milestones; says 'with our 2013 year-end cash balance projected to exceed $150 million, we believe we have sufficient capital to fund our operations into 2016'01/13 16:04 ET
NEW HAVEN, Conn. -- Achillion Pharmaceuticals, Inc. today reported progress on the Company's portfolio of proprietary compounds for the treatment of chronic hepatitis C (HCV) and outlined its 2014 milestones....
Achillion Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise over 13% on the day.
Synageva finished enrolling patients for its phase III study on sebelipase alfa.